Protara Tx (TARA): Net earnings per share growth forecast for next year
Protara Therapeutics (TARA) pays no dividends, as its financial stability depends on investments and R&D success. Analyst EPS growth targets for the next 12 months on the GURU.Markets terminal chart demonstrate a confidence vector, where the value -17.00 describes the current level. A high barrier to entry is driven by patents and FDA oversight, while development is limited to academic partnerships without M&A.
Financial and market metric breakdowns for protaratx.com (TARA)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Protara Therapeutics|TARA - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Protara Therapeutics, Inc.|TARA - Company Aggregate Debts|Debt to Book Capitalization Ratio Protara Therapeutics|TARA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Protara Therapeutics|Quick Liquidity Indicator protaratx.com
- net income and valuation ratios data:
TARA - Final Profit|Future Profit Protara Therapeutics|TARA - Market Price to Net Income Ratio|Forward P/E Multiple Protara Therapeutics|TARA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Protara Therapeutics|TARA - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Protara Therapeutics|TARA - Earnings per share for the trailing year|Quarterly EPS earnings growth protaratx.com|TARA - Earnings growth in current year|Net earnings per share growth forecast for next year Protara Therapeutics
- sales and revenue indicators:
Basic company analysis:TARA, Protara
Geopolitical isolation and logistical disruptions are seriously hindering the conduct of international clinical trials for Protara Therapeutics (TARA). Analyzing the expected growth dynamics of net income per share for next year, the investor observes aggregated analyst forecasts for future profitability. This metric measures the percentage change in EPS, reflecting market confidence in the commercialization of drugs. A positive trend signals the overcoming of regulatory barriers and a potential increase in the asset's value.
Competitor analysis for Protara Therapeutics
ONC (BeiGene Corp) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Corp HALO|Net earnings per share growth forecast for next year Revolution Medicines (RVMD)|AAPG: Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year CG Oncology CGON|Expected earnings per share trend next year URGN|BCAX - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Personalis Genomics|ERAS (Erasca, Inc.) - Expected earnings per share growth for next year|DCTH: Projected earnings per share increase next year|YMAB (Y-mAbs Therapeutics, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year Aura Biosciences Inc|Net earnings per share growth forecast for next year Candel Therapeutics (CADL)|ARAY (Accuray, Inc.) - Expected earnings per share trend next year|Earnings growth forecast for next year SLS (SELLAS Life Sciences Group)|Earnings growth forecast for next year actuatetherapeutics.com ACTU|CTOR: Expected earnings per share growth for next year|Expected earnings per share trend next year HURA (TuHURA Biosciences, Inc.)|FATE (Fate Therapeutics Corp) - Expected earnings per share growth for next year|WHWK: Projected earnings per share increase next year|TCRX (TScan Therapeutics Inc) - Earnings growth forecast for next year|CSBR: Expected earnings per share trend next year|Earnings growth forecast for next year XBIT|CVM - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year OS Therapies Inc OSTX|Expected earnings per share trend next year RADX|Artiva - Earnings growth forecast for next year|ANL - Earnings growth forecast for next year|Veru (VERU) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year TPST (Tempest Therapeutics Inc)|XLO (Xilio Therapeutics Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Enochian BioSciences RENB|Expected earnings per share growth for next year MURA (Mural Oncology plc)|Earnings growth forecast for next year kairospharma.com (KAPA)|OnKure Therapeutics - Expected earnings per share growth for next year|Projected earnings per share increase next year GDTC (CytoMed Therapeutics Ltd)|Curis Corp - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Apollomics, Inc. APLM|THAR: Earnings growth forecast for next year|Expected earnings per share growth for next year Advanced Biomed|Net earnings per share growth forecast for next year Genprex|Calidi Bio (CLDI) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year SBFM (Sunshine Biopharma, Inc.)|Projected earnings per share increase next year XBIO|Earnings growth forecast for next year SLRX (Salarius Pharmaceuticals)|Earnings growth forecast for next year purple-biotech.com PPBT|AONC - Net earnings per share growth forecast for next year|Expected earnings per share trend next year BGNE (BeiGene Ltd.)|CKPT: Earnings growth forecast for next year|elevationoncology.com (ELEV) - Earnings growth forecast for next year|ICAD (iCAD Inc.) - Earnings growth forecast for next year|Expected earnings per share growth for next year Ikena (IKNA)|Earnings growth forecast for next year NTBL|Earnings growth forecast for next year viracta.com (VIRX)|Net earnings per share growth forecast for next year MorphoSys Corp MOR|NAYA: Projected earnings per share growth rate for next year|Ascentage Pharma Group - Earnings growth forecast for next year
